Paces of Costly Care: Rare Disease Drug Access in Canada.

Clicks: 351
ID: 89245
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Pharmaceutical industry representatives and public drug plan managers hold competing visions of drug access, ones I theorize as "fast" and "slow" care paces. The relationship between free market imaginaries and population-based biopolitics is negotiated through these paces from within the flexible political category of rare disease. In this article, I explore expensive rare disease drug access in Canada's universal health system through a temporal lens. I show how two families navigate these powerful negotiations, asserting themselves as deserving of resources while finding ways to consider life and death outside of this clash between health system pragmatics and pharmaceutical promise.
Reference Key
mcguire2019pacesmedical Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors McGuire, Marlee;
Journal medical anthropology
Year 2019
DOI
10.1080/01459740.2019.1573229
URL
Keywords
value valorisation canada rare disease couverture universelle sanitaire l’accès aux medicaments maladies rares pharmaceutical access temporality temporalité universal health care

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.